NASDAQ:BIVI BioVie (BIVI) Stock Price, News & Analysis $0.41 -0.01 (-1.64%) (As of 07/5/2024 08:52 PM ET) Add Compare Share Share Today's Range$0.40▼$0.4350-Day Range$0.40▼$0.5052-Week Range$0.40▼$5.82Volume416,600 shsAverage Volume1.51 million shsMarket Capitalization$25.02 millionP/E RatioN/ADividend YieldN/APrice Target$6.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get BioVie alerts: Email Address BioVie MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside1,448.5% Upside$6.33 Price TargetShort InterestHealthy1.85% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.07 out of 5 starsMedical Sector515th out of 879 stocksPharmaceutical Preparations Industry241st out of 417 stocks 3.3 Analyst's Opinion Consensus RatingBioVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBioVie has only been the subject of 1 research reports in the past 90 days.Read more about BioVie's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.85% of the outstanding shares of BioVie have been sold short.Short Interest Ratio / Days to CoverBioVie has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioVie has recently decreased by 5.83%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioVie does not currently pay a dividend.Dividend GrowthBioVie does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BIVI. Previous Next 1.9 News and Social Media Coverage News SentimentBioVie has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for BioVie this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for BIVI on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows5 people have added BioVie to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioVie insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of BioVie is held by insiders.Percentage Held by InstitutionsOnly 4.59% of the stock of BioVie is held by institutions.Read more about BioVie's insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of BioVie is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioVie is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioVie has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about BioVie's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. About BioVie Stock (NASDAQ:BIVI)BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.Read More BIVI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIVI Stock News HeadlinesJuly 4, 2024 | americanbankingnews.comShort Interest in BioVie Inc. (NASDAQ:BIVI) Declines By 5.8%July 2, 2024 | americanbankingnews.comBioVie (NASDAQ:BIVI) Receives New Coverage from Analysts at ThinkEquityJuly 8, 2024 | Crypto 101 Media (Ad)[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… June 20, 2024 | globenewswire.comBioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD CongressJune 12, 2024 | globenewswire.comJoin BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26May 22, 2024 | finance.yahoo.comBioVie’s Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease PatientsMay 22, 2024 | globenewswire.comBioVie's Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson's Disease PatientsMay 18, 2024 | nz.finance.yahoo.comBIVI Jul 2024 0.500 putJuly 8, 2024 | Crypto 101 Media (Ad)[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… May 14, 2024 | finance.yahoo.comBioVie Inc. (BIVI)May 2, 2024 | stockhouse.comInvestors who Lost Money with BioVie Inc. (NASDAQ: BIVI) Shares Should Contact the Shareholders Foundation in Connection with Pending LawsuitApril 29, 2024 | proactiveinvestors.comBioVie secures $13.1M funding from US Department of Defense for Long COVID treatmentApril 29, 2024 | globenewswire.comBioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVIDApril 25, 2024 | finance.yahoo.comBioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker EndpointsApril 25, 2024 | proactiveinvestors.comBioVie presents new data showing lead drug asset may promote healthier agingApril 25, 2024 | globenewswire.comBioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer's Disease and Biomarker EndpointsApril 19, 2024 | benzinga.comLatest News for BioVie Stock (NASDAQ:BIVI)April 18, 2024 | globenewswire.comBioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and InflammationSee More Headlines Receive BIVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioVie and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/07/2024Next Earnings (Estimated)8/21/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BIVI CUSIPN/A CIK1580149 Webbioviepharma.com Phone(775) 888-3162FaxN/AEmployees18Year FoundedN/APrice Target and Rating Average Stock Price Target$6.33 High Stock Price Target$11.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,448.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,260,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-294.42% Return on Assets-129.46% Debt Debt-to-Equity RatioN/A Current Ratio2.45 Quick Ratio2.45 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.42 per share Price / Book0.97Miscellaneous Outstanding Shares61,170,000Free Float57,802,000Market Cap$25.02 million OptionableOptionable Beta0.74 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Cuong Viet Do M.B.A. (Age 58)President, CEO & Director Comp: $1.08MMs. Joanne Wendy Kim CPA (Age 69)CFO, Treasurer & Corporate Secretary Comp: $397.38kDr. Joseph M. Palumbo M.D. (Age 64)Executive VP of R&D and Chief Medical Officer Comp: $722kMr. Clarence N. Ahlem (Age 69)Senior Vice President of Operations Dr. Penelope Markham Ph.D. (Age 58)Senior Vice President of Liver Disease Program Ms. Denise SmithSenior Vice President of Manufacturing & DevelopmentDr. Christopher L. Reading Ph.D. (Age 76)Senior Vice President of Alzheimer's Disease Program Ms. Sarah Overton Hoit (Age 56)Chief Social Impact Officer More ExecutivesKey CompetitorsEnlivex TherapeuticsNASDAQ:ENLVAytu BioPharmaNASDAQ:AYTUCervoMedNASDAQ:CRVORAPT TherapeuticsNASDAQ:RAPTInterCureNASDAQ:INCRView All CompetitorsInsiders & InstitutionsTorno Capital LLCSold 21,800 shares on 5/15/2024Ownership: 0.000%Sheaff Brock Investment Advisors LLCBought 37,762 shares on 5/14/2024Ownership: 0.129%CVI Holdings LLCBought 599,897 shares on 5/7/2024Ownership: 1.503%Cuong V DoBought 10,000 shares on 11/30/2023Total: $17,800.00 ($1.78/share)Steve GorlinSold 8,560 sharesTotal: $26,108.00 ($3.05/share)View All Insider TransactionsView All Institutional Transactions BIVI Stock Analysis - Frequently Asked Questions How have BIVI shares performed this year? BioVie's stock was trading at $1.26 at the beginning of 2024. Since then, BIVI stock has decreased by 67.5% and is now trading at $0.4090. View the best growth stocks for 2024 here. How were BioVie's earnings last quarter? BioVie Inc. (NASDAQ:BIVI) issued its earnings results on Tuesday, May, 14th. The company reported ($0.20) earnings per share (EPS) for the quarter. How do I buy shares of BioVie? Shares of BIVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BIVI) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIVI Stock Alerts